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Letters to the Editor
European Journal of Heart Failure 9 (2007) 962–964
www.elsevier.com/locate/ejheart
Dear Sir,
Increased resting heart rate is inversely associated with life
expectancy [1]. Heart rate reduction with beta-blocker
treatment has been shown to confer survival benefit in patients
with coronary heart disease [2,3]. Daniela Dobre et al. [4]
observed that beta-blocker treatment in patients with heart
failure and preserved ejection fraction reduce mortality by
43%. They refer to a reduction in heart rate as a possible
mechanism of benefit. Baseline average heart rate in their
study was quite high, 97.6 beats per minute with a large
potential for reduction. The high resting heart rate is associated
with poor prognosis and benefit might be expected with heart
rate reduction if cardiac output can be maintained. The
information on heart rate reduction and survival benefit in
heart failure trials is limited. Daniela Dobre and co-workers
should provide data on changes in heart rate or blood pressure,
which is crucial in understanding the clinical implications of
beta-blocker treatment. The information may also be support-
ive of heart rate reduction as their proposed mode of action.
The use of high and low doses of the beta-blockers also
warrants some information on the respective changes in resting
heart rates among these patients.
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Prescription of beta-blockers in patients with advanced
heart failure and preserved left ventricular ejection
fraction. Clinical implications and survival
Dear Sir,
We thank Professor Kjekshus for his comments on our
paper [1] and agree that reducing heart rate (HR) with beta-
blockers might be one of the mechanisms of action by which
these drugs work in heart failure (HF) [2]. He correctly points
out, that in patients with coronary artery disease, there is an
association between the degree of HR lowering by beta-
blockers and the magnitude of survival benefit, and wonders
whether we can provide data on HR (and blood pressure
response) after treatment.
We agree that this data would have been interesting, but
unfortunately no follow-up data on HR (and blood pressure)
were available in this observational-cohort of patients, and
we are therefore not able to comment on the relation between
HR lowering and survival in this population.
The evidence for an association between HR lowering and
survival benefit is less clear in HF. Although in CIBIS II, the
greatest HR reduction was associated with the largest survival
benefit [2], in the larger MERIT-HF trial, no such relation
could be observed [3]. Moreover, the presence of atrial
fibrillation (AF) in patients with HF may also play a role in
this respect. Recently, it was shown that while patients with
AF had a similar reduction in HR as those with sinus rhythm
at baseline, there was no effect on survival in the AF group
[4], and a similar finding was reported in the CIBIS-II trial
[2]. Interestingly, as many as 45% of patients had AF in our
observational study [1] and it would have been interesting to
compare the effects on HR reduction and survival in both
patients with AF and in those with sinus rhythm.
Another factor in both survival and reduction of HR in HF
is of course the dose of beta-blocker used. In our study, we
found that higher doses of beta-blockers exerted a higher
benefit than lower doses [1]. Similarly, we recently showed
in a post-hoc analysis from the SENIORS study that higher
maintenance doses of nebivolol achieved a higher benefit
than lower doses, while patients unable to tolerate any dose
had the worst prognosis [5]. Only one randomised trial has so
far prospectively examined the effect of beta-blocker dose in
HF patients, and this MOCHA study [6] showed a dose-
related improvement in ejection fraction and survival while
no dose-related reduction in HR and blood pressure was
associated with the clinical outcome.
1388-9842/$ - see front matter © 2007 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
In summary, although we generally agree with Professor
Kjekshus about HR reduction and survival, this relation is
less pronounced in HF, while AF and dose also play a role.
More prospective data are needed on this subject.
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RAS blockers: Does sex matter? Re: Sex differences in
the effectiveness of ARB and ACEI in patients with
congestive heart failure — A population study: Marie
Hudson et al. European Journal of Heart Failure 9 (2007)
602–609
The retrospective analysis by Hudson et al. [1] suggests
that the global mortality of male patients discharged post
hospitalization for CHF with a prescription for ARB was no
different than for an ACEI, with a survival advantage for
females prescribed ARB. Randomized prospective trials
would suggest otherwise.
A meta-analysis of trials that randomized ARB vs. ACEI
(ELITE I, ELITE II, OPTIMAAL, VALIANT, DETAIL;
n=19,419, 99% with CHF) [2] found a greater global
mortality with ARB than ACEI (OR 1.06 .99–1.14, p=.1).
The majority of patients were post an acute MI. In
OPTIMAAL[3] (n=5477), cardiovascular mortality was
significantly increased with losartan as compared to captopril
(OR 1.17 CI 1.01–1.34) despite a mean follow up of just
2.7 years. The mortality rate in VALIANT (n=9818) [4] was
not statistically different for valsartan and captopril (19.9%
vs.19.5% respectively). Although VALIANT was event
driven, one could argue that the follow-up of 24.7 months
was just simply too short to differentiate drug efficacy
considering the cardiovascular benefits of ACEI in SAVE and
SOLVD, both placebo controlled trials, took 3.5 years to
achieved significance. VALIANT was a negative “superior-
ity” trial and as such, the “apparent” absence of a difference in
mortality does not rule out that a clinically important
difference exists, nor can it prove statistical equivalence.
In Hudson's [1] retrospective analysis, 13% of patients
were prescribed ARB over ACEI despite guidelines recom-
mending otherwise. Bias on the part of physicians is the likely
explanation and statistical models can not adjust for this.
Follow-up of only 2–3 years with relatively small numbers
prescribed ARB (n=2587) as compared to ACEI (n=17,111)
may accentuate any bias and contribute to conclusions that
are erroneous. This may account for the apparent survival
advantage in females with ARB, but not in males, with the
inference being that ACEI have reduced efficacy in females.
This appears not to be so, as a meta-analysis of placebo
controlled CHF trials with ACEI demonstrated a similar
survival advantage in women (n=2373, HR 0.80, 95% CI
0.76–.85) [5] as in men.
ACEI are well established as the preferential therapy over
ARB for CHF, regardless of gender. A multiplicity of meta-
analyses supports a similar conclusion for all “high risk
patients”. In a meta-analysis of 150,943 patients[2], ACEI
reduced the risk of MI by 14% (pb .00001) and CV death by
12% (pb .0005). Four separate meta-analyses of ARB
(n=56,254–68,711)[2,6–8] failed to demonstrate any reduc-
tion in either MI or CV death. Two meta-regression analyses
(n=136,838 and 179,122) [9,10] suggest that the benefits of
ACEI on the combined endpoint of MI and CV death was
significantly greater than could be predicted by blood
pressure lowering alone (9% and 12% respectively).
“Blood pressure independent” effects are unique to ACEI
[9,10] and are not evident with ARB [9].
A retrospective analysis can at best generate plausible
hypotheses — with the emphasis on the word “plausible”.
Further division into sub-groups adds little, as one sub-group
will tend to do better, and the other worse, than the overall
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